Benefit of tamoxifen in estrogen receptor positive DCIS of the breast

Por Fausto, Petrelli, Barni, Sandro
Publicado em 2012

Turn on the TORCH before treat your patients: a lesson from a first line study in advanced NSCLC

Por Petrelli, Fausto, Barni, Sandro
Publicado no Transl Lung Cancer Res (2012)

Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials

Por Petrelli, Fausto, Barni, Sandro
Publicado no Transl Lung Cancer Res (2013)

Axillary dissection compared to sentinel node biopsy for the treatment of pathologically node-negative breast cancer: a meta-analysis of four randomized trials with long-term follo...

Por Petrelli, Fausto, Lonati, Veronica, Barni, Sandro
Publicado no Oncol Rev (2012)

Preventing or treating anti-EGFR related skin rash with antibiotics?

Por Petrelli, Fausto, Borgonovo, Karen, Barni, Sandro
Publicado no Ann Transl Med (2016)

Gastric cancer: toward a cisplatin-free disease?

Por Petrelli, Fausto, Barni, Sandro, Cascinu, Stefano, Zaniboni, Alberto
Publicado em 2014

TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?

Por Petrelli, Fausto, Barni, Sandro, Bertocchi, Paola, Zaniboni, Alberto
Publicado no BMC Cancer (2016)

Optimizing use of opiates in the management of cancer pain

Por Mandalà, Mario, Moro, Cecilia, Labianca, Roberto, Cremonesi, Marco, Barni, Sandro
Publicado em 2006

The Risk for Anemia with Targeted Therapies for Solid Tumors

Por Barni, Sandro, Cabiddu, Mary, Guarneri, Paolo, Lonati, Veronica, Petrelli, Fausto
Publicado em 2012

Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials

Por Petrelli, Fausto, Borgonovo, Karen, Cabiddu, Mary, Ghilardi, Mara, Lonati, Veronica, Barni, Sandro
Publicado no J Gastrointest Oncol (2017)

Cisplatin or Not in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis

Por Petrelli, Fausto, Zaniboni, Alberto, Coinu, Andrea, Cabiddu, Mary, Ghilardi, Mara, Sgroi, Giovanni, Barni, Sandro
Publicado em 2013

The effect of low-molecular-weight heparin in cancer patients: the mirror image of survival?

Por Barni, Sandro, Bonizzoni, Erminio, Verso, Melina, Gussoni, Gualberto, Petrelli, Fausto, Perrone, Tania, Agnelli, Giancarlo
Publicado em 2014

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials

Por Petrelli, Fausto, Coinu, Andrea, Cabiddu, Mary, Borgonovo, Karen, Ghilardi, Mara, Lonati, Veronica, Barni, Sandro
Publicado no Medicine (Baltimore) (2016)

Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study

Por Barni, Sandro, Labianca, Roberto, Agnelli, Giancarlo, Bonizzoni, Erminio, Verso, Melina, Mandalà, Mario, Brighenti, Matteo, Petrelli, Fausto, Bianchini, Carlo, Perrone, Tania, Gasparini, Giampietro
Publicado em 2011

Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis

Por Petrelli, Fausto, Berenato, Rosa, Turati, Luca, Mennitto, Alessia, Steccanella, Francesca, Caporale, Marta, Dallera, Pierpaolo, de Braud, Filippo, Pezzica, Ezio, Di Bartolomeo, Maria, Sgroi, Giovanni, Mazzaferro, Vincenzo, Pietrantonio, Filippo, Barni, Sandro
Publicado no J Gastrointest Oncol (2017)

Dose-Dense FEC Followed by Dose-Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study

Por Clavarezza, Matteo, Bordonaro, Roberto, Daniele, Bruno, Ferrandina, Gabriella, Barni, Sandro, Turazza, Monica, Coati, Francesca, De Matteis, Andrea, De Placido, Sabino, Cognetti, Francesco, Olmeo, Nina Antonina, Carrozza, Francesco, Bruzzi, Paolo, Del Mastrol, Lucia
Publicado em 2013

Dose-Dense FEC Followed by Dose-Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study

Por Clavarezza, Matteo, Bordonaro, Roberto, Daniele, Bruno, Ferrandina, Gabriella, Barni, Sandro, Turazza, Monica, Coati, Francesca, De Matteis, Andrea, De Placido, Sabino, Cognetti, Francesco, Olmeo, Nina Antonina, Carrozza, Francesco, Bruzzi, Paolo, Del Mastro, Lucia
Publicado em 2013

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type...

Por Eng, Cathy, Bessudo, Alberto, Hart, Lowell L., Severtsev, Aleksey, Gladkov, Oleg, Müller, Lothar, Kopp, Mikhail V., Vladimirov, Vladimir, Langdon, Robert, Kotiv, Bogdan, Barni, Sandro, Hsu, Ching, Bolotin, Ellen, von Roemeling, Reinhard, Schwartz, Brian, Bendell, Johanna C.
Publicado no Int J Cancer (2016)

The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib

Por Faloppi, Luca, Bianconi, Maristella, Giampieri, Riccardo, Sobrero, Alberto, Labianca, Roberto, Ferrari, Daris, Barni, Sandro, Aitini, Enrico, Zaniboni, Alberto, Boni, Corrado, Caprioni, Francesco, Mosconi, Stefania, Fanello, Silvia, Berardi, Rossana, Bittoni, Alessandro, Andrikou, Kalliopi, Cinquini, Michela, Torri, Valter, Scartozzi, Mario, Cascinu, Stefano
Publicado no Oncotarget (2015)

Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Mul...

Por Gori, Stefania, Inno, Alessandro, Rossi, Valentina, Turazza, Monica, Fiorio, Elena, Fabi, Alessandra, Bisagni, Giancarlo, Foglietta, Jennifer, Santini, Daniele, Pavese, Ida, Pellegrino, Arianna, Zambelli, Alberto, Vici, Patrizia, Leonardi, Vita, Barni, Sandro, Saracchini, Silvana, Bogina, Giuseppe, Marchetti, Fabiana, Duranti, Simona, Lunardi, Gianluigi, Montemurro, Filippo
Publicado no PLoS One (2016)